Search PubMed⌕ Search

Biomedical subjects

J B Craig

Publications and source records attributed to J B Craig.

67 records · Page 4Linked to original sources

Toward the development of a standard reference cholera antitoxin.

The need for a reference cholera antitoxin to serve as a standard for the calibration of cholera enterotoxin and toxoid as well as for measurement of the antitoxin response in animals and patients was recognized by the NIH Cholera Advisory Committee, NIAID, DHEW, USA. Two cholera antitoxins have been used for several years as provisional references, but neither was considered to embody all of the properties of an ideal standard. Accordingly, a lot of cholera antitoxin was prepared by immunization of goats with a formalinized, highly purified cholera toxin adsorbed on aluminum phosphate adjuvant. Booster injections were given at 8, 16 and 24 weeks. Plasma samples obtained from the 25 to 27 week bleedings were converted to serum, pooled, and freeze-dried. This serum possessed both high and constant toxin neutralizing activity in rabbit skin, rabbit ileal segment, mice, Y-1 adrenal cells and Chinese hamster ovary cells, and had high avidity by the rabbit skin assay. Hemagglutination tests gave identical values. It was shown to be highly specific by gel diffusion, but flocculation was relatively poor. On the basis of specificity, high avidity and toxin-neutralizing capacity this goat antitoxin (NIH Lot 1) was considered superior to previous provisional standards and is proposed as a satisfactory standard reference reagent.

Antibodies, Bacterial↗

Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study.

Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study of AMF in disseminated malignant melanoma. Twenty patients, eleven males and nine females, with biopsy proven malignant melanoma, performance status 0-2; median age 59 (range 29-74), and no previous chemotherapy, were treated with AMF 300 mg/m2/day by 60 min i.v. infusion for five days repeated every three weeks. Fifteen patients had lung (9 patients) and/or liver (8 patients) involvement. None had known brain metastasis at entry. All 20 patients were evaluated for response and toxicity. Six patients had stable disease and fourteen had increasing disease. With 0/20 responses, the upper 95% confidence limit for the response rate was 14%. The median survival time was 5.7 months. Hematologic toxicity was dose limiting with the incidence of leucopenia 45% and thrombocytopenia 20%. The nonhematologic toxicities included nausea and vomiting (60%), alopecia (20%), headaches (15%), diarrhea (10%), and phlebitis (10%). We conclude that AMF administered at this dose and schedule is not active in the treatment of patients with malignant melanoma, previously untreated with chemotherapy.

Adenine↗